Summary Several studies have focused on the role of p53 inactivation in cervical cancer, either by inactivating mutations in the TP53 gene or by degradation of the p53 protein by human papillomavirus (HPV). In this study, primary cervical carcinomas from 365 patients were analysed for presence of HPV using both consensus primer-sets and type-specific primer-sets. Nineteen samples were determined to have no or low virus load, and were selected for further analyses: mutation screening of the TP53 gene using constant denaturant gel electrophoresis (CDGE) followed by sequencing, and protein expression of p53, MDM2 and p21 using immunohistochemistry (IHC). Mutations in the TP53 gene were found in eight samples (42%0/). Elevated p53 protein expression was significantty associated with presence of a mutation (P < 0.007). P21 protein expression was detected in 16 of the 19 carcinomas. No p21 expression was seen in normal cervical tissue. Two samples, both with wild-type p53, had elevated MDM2 expression. Compared with a previous study from our group, of mainly HPV-positive cervical carcinomas, in which only one sample was found to contain a TP53 mutation, a significantly higher mutation frequency (P < 0.001) was found among the carcinomas with no or low virus load. Although p53 inactivation pathways are not detected in every tumour, our study supports the hypothesis that p53 inactivation, either by binding to cellular or viral proteins or by mutation, is essential in the development of cervical carcinomas.
Keywords: human papillomavirus negative cervical carcinoma; TP53 mutation; p53; p21 and MDM2 expression Over recent years. data supporting the hypothesis that specific types of human papillomavirus (HPV) play a central role in the pathogenesis of cervical dysplasia and invasive cancer of the cervix have emerged (Bosch et al. 1995) . The viral E6 and E7 genes of the high-risk HPV are regularly expressed in HPV-positive tumours (Durst et al. 1992 : Jiko et al. 1994 : Ikenberg et al. 1995 : MildeLangosch et al. 1995 : Miwa et al. 1995 . Hence. alternative pathways for p53 inactivation have been discussed. MDM2 is a negative cellular regulator of p53 protein activity (Kubbutat et al. 1997) . Amplification of MDM2 could lead to p53 inactivation in HPV-negative tumours. Recent studies have shown that MDM2 amplification is rare in primary cervical carcinoma (Ikenberg. 1995: Miwa, 1995) .
From a series of 365 primary cervical carcinomas analysed for HPV with several different primers -both consensus and type specific -19 tumours with no or low virus load were selected for further analyses. These samples were analysed for TP53 mutation by constant denaturant gel electrophoresis (CDGE) followed by sequencing as well as immunohistochemistry to detect p53. p2l (Waf1) and MDM2 protein expression.
MATERIALS AND METHODS Material
Material for this study was obtained from 365 patients with primary cervical carcinomas admitted to the Department of Gynaecological Oncology. The Norwegian Radium Hospital. in the period from 1988 to 1993. The HPV results of 361 of these have previously been published (Karlsen et al. 1996) . In addition. three clear-cell carcinomas and one small-cell carcinoma were included. DNA extraction was performed with standard methods (phenol-chloroform extraction and ethanol precipitation). Nineteen cases were judged negative or weak positive for HPV. The histological types of these samples are shown in Table 1 . Table 2 . 
HPV detection
The primers used for PCR were the consensus primers Oli of the LI gene (modified from Jenkins et al. 1991 : Karlsen et al. 1996 . My of the LI gene (Manos et al. 1989 ). Gp of the LI (de Roda Husman et al. 1995) and Cp of the El gene (Tieben et al. 1993 ). In addition, type-specific primers were used for HPV type 11. 16. 18.
31. 33 and 35. Details of the polymerase chain reaction (PCR) methods are described in detail elsewhere (Karlsen et al, 1996 
TP53 mutation analysis using CDGE
The 19 samples with no or low HPV load were analysed for mutation of exons 5-8 of the TP53 gene using CDGE (Andersen and B0rresen. 1995; B0rresen. 1996) Figure 1 . Elevated p53 protein expression was significantly associated with the presence of TP53 mutation (P < 0.007). Two mutated samples showed no p53 protein expression. One of these (F763) revealed an insertion after sequencing, leading to a frameshift and a stop in codon 207/208. In the other tumour (F665). the mutation was not detected by sequencing, most probably because of a mutation present only in a small fraction of the cells as judged by the CDGE analyses.
Ten cases of normal cervix obtained from hysterectomy specimens were immunostained for p53. p2 l/Waf-1 and MDM2 protein and were all scored negative. MDM2 expression was seen in two of the cervical carcinoma samples. both with a wild-type TP53 gene. Sixteen of the 19 carcinomas showed elevated expression of p2 1. The three samples with no detectable p21 protein expression were all mutated in the TP53 gene.
British Joumal of Cancer (1998) 78(1) HPV 16 is predominantly found, in squamous cell carcinomas, whereas type 18 is most commonly found in adenocarcinomas of the cervix (Bosch et al, 1995 (Borresen et al, 1992 , Helland et al, 1993 , performed on predominantly HPV-positive material, this series of HPV-negative/ weak positive samples reveals a significantly higher frequency of TP53 mutations (P < 0.001).
Three samples revealed two different TP53 mutations (Table 2) . Two of these samples (H146, H148) had a C -* T transversion in codon 181, leading to an arginine to cystein amino acid substitution. This mutation has previously been detected as a germline mutation in an early-onset breast cancer patient (Sidransky et al, 1992) . We cannot rule out the possibility that the codon 181 alteration is a rare germilne variant distributed within the normal population. Unfortunately, no germline DNA from these two patients was available. In addition to viral gene products, several cellular proteins are implicated in the inactivation of p53, and could be responsible for p53 inactivation in HPV-negative carcinomas. In this study only two samples had elevated MDM2 expression, both among the 11 samples with no mutation detected in the TP53 gene. Studies on larger series analysing both MDM2 gene amplification and protein expression are required to identify further the importance of MDM2 in cervical carcinomas.
In this series of HPV-negative or weakly HPV-positive cervical carcinoma samples, TP53 mutation was found in a relatively high percentage (42%). Only 2% of the samples had neither TP53 mutation, HPV infection nor MDM2 overexpression, indicating that p53 inactivation is important for the development of the majority of cervical carcinomas.
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